The number of patients undergoing valve repair and replacement or catheter-based interventions has continuously increased during recent decades, such that today in Europe approximately 50,000 cases are reported each year (1). Despite substantial progress having been made in surgery as well as in catheter-based valve procedures, patients who have undergone valvar interventions face a permanent risk of complications. These may be due to the intervention itself, to the underlying cardiac disease, and/or to any medication considered necessary. Although some of these complications represent a constant hazard during follow up (for example, late prosthetic valve endocarditis, PVE), others - such as periprosthetic leaks or the recurrence of mitral regurgitation after valve repair - have an early and decreasing risk, while yet others (such as primary tissue failure of bioprostheses) represent a later and increasing risk during follow up. The underlying cardiac disease may also harm the patient, for example by the occurrence of arrhythmias or congestive heart failure. As the risk of any of these complications remains throughout life, regular medical care is mandatory.
|Number of pages||15|
|Journal||Journal of Heart Valve Disease|
|Publication status||Published - Nov 1 2007|
ASJC Scopus subject areas
- Cardiology and Cardiovascular Medicine